SweepCast
Start Trial
Pricing
Support
Contact
Blog
Member Login
Start Trial ->
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
February 2, 2024
CNBC
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p
SweepCast